← Back to Clinical Trials
Recruiting NCT05386719

NCT05386719 Cardiometabolic Screening Program

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05386719
Status Recruiting
Phase
Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 450 participants
Start Date 2022-06-03
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PrescreeningScreening and EnrollmentBaseline

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 450 participants in total. It began in 2022-06-03 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional resources for management.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of early stage breast cancer * Completed local and/or systemic therapy at least 3 months ago * Receiving medical oncology care at through the breast cancer clinics at Johns Hopkins Medical Institute, including the Sidney Kimmel Comprehensive Cancer Center in Baltimore MD and Green Spring Station in Lutherville-Timonium MD, and Sibley Memorial Hospital in Washington D.C. * Read and speak English Exclusion Criteria: * Metastatic breast cancer

Contact & Investigator

Central Contact

Hopkins Breast Trials

✉ HopkinsBreastTrials@jhmi.edu

📞 410-614-1361

Principal Investigator

Jennifer Sheng, M.D.

PRINCIPAL INVESTIGATOR

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Frequently Asked Questions

Who can join the NCT05386719 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05386719 currently recruiting?

Yes, NCT05386719 is actively recruiting participants. Contact the research team at HopkinsBreastTrials@jhmi.edu for enrollment information.

Where is the NCT05386719 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT05386719 clinical trial?

NCT05386719 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The principal investigator is Jennifer Sheng, M.D. at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial plans to enroll 450 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology